Elite in Epidermolysis Bullosa

Dr. Anna L. Bruckner

Dermatology
13123 E 16th Ave, Children's Hospital Colorado, 
Aurora, CO 
Accepting New Patients
Elite in Epidermolysis Bullosa
13123 E 16th Ave, Children's Hospital Colorado, 
Aurora, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anna Bruckner is a Dermatologist in Aurora, Colorado. Dr. Bruckner is rated as an Elite provider by MediFind in the treatment of Epidermolysis Bullosa. Her top areas of expertise are Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa, and Dowling-Meara Epidermolysis Bullosa Simplex. Dr. Bruckner is currently accepting new patients.

Her clinical research consists of co-authoring 76 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 39 articles and participated in 8 clinical trials in the study of Epidermolysis Bullosa.

Specialties
Dermatology
Licenses
Dermatology in CO
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 14 Less Insurance Carriers -

Locations

13123 E 16th Ave, Children's Hospital Colorado, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Use of Otoscope as a Non-invasive Tool for Diagnosis of Pilomatricoma
Use of Otoscope as a Non-invasive Tool for Diagnosis of Pilomatricoma
Enrollment Status: Completed
Publish Date: December 27, 2024
A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2024
Intervention Type: Biological
Study Drug: FCX-007 (Dabocemagene Autoficel)
Study Phase: Phase 3
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Drug
Study Drug: Oleogel-S10
Study Phase: Phase 3
Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Enrollment Status: Terminated
Publish Date: March 30, 2023
Intervention Type: Drug
Study Drug: Sirolimus
Study Phase: Phase 2
A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Drug, Other
Study Drug: Sildenafil
Study Phase: Phase 2
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Open-Label Study of PTR-01 in Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Phase 2 Open-Label Study of PTR-01 in Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Drug: PTR-01
Study Phase: Phase 2
A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene
A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene
Enrollment Status: Terminated
Publish Date: August 25, 2021
Intervention Type: Drug
Study Drug: QR-313
Study Phase: Phase 1/Phase 2
A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Enrollment Status: Completed
Publish Date: March 09, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

76 Total Publications

Methodological Concerns in the EASE Study of Oleogel-S10 for Epidermolysis Bullosa: reply from authors.
Methodological Concerns in the EASE Study of Oleogel-S10 for Epidermolysis Bullosa: reply from authors.
Journal: The British journal of dermatology
Published: September 10, 2025
Similar Doctors
Distinguished in Epidermolysis Bullosa
Dr. Emily S. Gorell
Dermatology | Pediatrics
Distinguished in Epidermolysis Bullosa
Dr. Emily S. Gorell
Dermatology | Pediatrics

University Physicians Incorporated

1665 Aurora Ct, 
Aurora, CO 
 (0.2 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Emily Gorell is a Dermatologist and a Pediatrics provider in Aurora, Colorado. Dr. Gorell is rated as an Advanced provider by MediFind in the treatment of Epidermolysis Bullosa. Her top areas of expertise are Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Woolly Hair Syndrome, and Dominant Dystrophic Epidermolysis Bullosa. Dr. Gorell is currently accepting new patients.

Experienced in Epidermolysis Bullosa
Dr. Torunn E. Sivesind
Dermatology
Experienced in Epidermolysis Bullosa
Dr. Torunn E. Sivesind
Dermatology
1665 Aurora Ct, 
Aurora, CO 
 (0.2 miles away)
720-848-4000
Languages Spoken:
English
See accepted insurances

Torunn Sivesind is a Dermatologist in Aurora, Colorado. Dr. Sivesind is rated as an Advanced provider by MediFind in the treatment of Epidermolysis Bullosa. Her top areas of expertise are Erysipelas, Basal Cell Skin Cancer, Atopic Dermatitis, Cellulitis, and Septoplasty.

David A. Norris
Experienced in Epidermolysis Bullosa
Dr. David A. Norris
Dermatology
Experienced in Epidermolysis Bullosa
Dr. David A. Norris
Dermatology
12605 E 16th Ave, 
Aurora, CO 
 (0.4 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Norris is a Dermatologist in Aurora, Colorado. Dr. Norris is rated as a Distinguished provider by MediFind in the treatment of Epidermolysis Bullosa. His top areas of expertise are Alopecia Areata, Autosomal Recessive Hypotrichosis, Eosinophilic Fasciitis, and Malignant Hypertension. Dr. Norris is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bruckner's expertise for a condition
ConditionClose
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile